NeuroOne Medical Technologies Corporation filed a certificate of amendment to effect a 1-for-6 reverse stock split of its common stock, effective April 15, 2026 at 5:00 p.m. ET, with trading on a split-adjusted basis commencing April 16, 2026.
Key takeaways
Board approved 1-for-6 reverse stock split on April 3, 2026, following stockholder approval at annual meeting on same date.
Every 6 pre-split shares automatically convert to 1 post-split share; no fractional shares issued, cash paid instead based on closing price.
Proportional adjustments to equity incentive plans, stock options, warrants; authorized shares and par value unchanged.
New CUSIP 64130M308; trading continues under NMTC on Nasdaq Capital Market starting April 16, 2026.
Filed Certificate of Amendment on April 14, 2026 as Exhibit 3.1.